多囊卵巢综合征女性的非酒精性脂肪性肝病与阻塞性睡眠呼吸暂停
综述指出多囊卵巢综合征(PCOS)女性中非酒精性脂肪性肝病(NAFLD)和阻塞性睡眠呼吸暂停常被低估;PCOS女性NAFLD风险为体重匹配健康对照的2-4倍且不依赖体质指数;胰岛素抵抗与高雄激素血症共同参与致病;NAFLD治疗应包括生活方式干预,胰高血糖素样肽1受体激动剂显示初步效果但需随机试验证实,复方口服雌激素-孕激素避孕药可能通过降低高雄激素血症获益。
要点
- PCOS女性NAFLD风险为体重匹配健康对照的2-4倍,且不依赖体质指数。
- NAFLD可进展为非酒精性脂肪性肝炎和/或晚期肝纤维化,并增加2型糖尿病、心血管事件、总死亡及肝外癌症风险。
- PCOS合并NAFLD的治疗应包括生活方式干预;胰高血糖素样肽1受体激动剂显示初步效果但需随机试验证实。
核心结论
- PCOS女性中NAFLD和阻塞性睡眠呼吸暂停常被低估,NAFLD风险为体重匹配健康对照的2-4倍且不依赖体质指数。
- NAFLD治疗应包括生活方式干预;胰高血糖素样肽1受体激动剂显示初步效果但需随机试验证实;复方口服雌激素-孕激素避孕药可能通过降低高雄激素血症获益。
- 阻塞性睡眠呼吸暂停在超重和肥胖PCOS女性中最常见,患病率超过体重相似的非PCOS女性,未治疗可加重胰岛素抵抗、糖耐量异常和高血压。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- PCOS女性NAFLD风险为体重匹配健康对照的2-4倍,且不依赖体质指数。
- 胰岛素抵抗与高雄激素血症共同在NAFLD发病机制中起核心作用。
- NAFLD与2型糖尿病、心血管事件、总死亡及肝外癌症风险增加相关。
- 阻塞性睡眠呼吸暂停在超重和肥胖PCOS女性中最常见,患病率超过体重相似的非PCOS女性。
- 阻塞性睡眠呼吸暂停未治疗可促发或加重胰岛素抵抗、糖耐量异常和高血压。
关键数值与推荐
- PCOS女性NAFLD风险为体重匹配健康对照的2-4倍。
- NAFLD治疗应包括生活方式干预。
- 胰高血糖素样肽1受体激动剂在PCOS合并NAFLD患者中显示初步效果,但需未来随机试验证实。
- 复方口服雌激素-孕激素避孕药可能通过降低高雄激素血症提供获益。
临床怎么用
- PCOS女性应认识NAFLD和阻塞性睡眠呼吸暂停常被低估。
- NAFLD治疗应包括生活方式干预。
- 胰高血糖素样肽1受体激动剂在PCOS合并NAFLD中显示初步效果,但作者指出需未来随机试验证实。
- 复方口服雌激素-孕激素避孕药可能通过降低高雄激素血症提供获益,作者认为可能有益。
- 阻塞性睡眠呼吸暂停未治疗可促发或加重胰岛素抵抗、糖耐量异常和高血压。
局限性
- 胰高血糖素样肽1受体激动剂在PCOS合并NAFLD中的获益需未来随机试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea are frequently associated with polycystic ovary syndrome (PCOS) but remain underrecognized. Women with PCOS have a 2-4 times higher risk of NAFLD independent of body mass index than healthy weight-matched controls. Insulin resistance and hyperandrogenemia together play a central role in the pathogenesis of NAFLD. Timely diagnosis of NAFLD is important because its progression can lead to nonalcoholic steatohepatitis and/or advanced liver fibrosis that can eventually result in liver-related mortality. The presence of NAFLD has also been associated with increased risks of type 2 diabetes, cardiovascular events, overall mortality, and extrahepatic cancers. The treatment of NAFLD in PCOS should include lifestyle interventions. Glucagon-like peptide 1 receptor agonists have shown promising results in patients with PCOS and NAFLD, but future randomized trails are needed to confirm this benefit. Likewise, the use of combined oral estrogen-progestin contraceptives may provide a benefit by decreasing hyperandrogenemia. Sleep disordered breathing is common among women with PCOS and is responsible for a number of cardiometabolic derangements. Obstructive sleep apnea is most often found in overweight and obese women with PCOS, but as is the case with NAFLD, its prevalence exceeds that of women who are of similar weight without PCOS. Left untreated, obstructive sleep apnea can precipitate or exacerbate insulin resistance, glucose intolerance, and hypertension.
引用
- Doycheva I, Ehrmann DA. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril. 2022. PMID: 35512974. doi:10.1016/j.fertnstert.2022.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。